Substituted 3-aminoquinuclidines
    1.
    发明授权
    Substituted 3-aminoquinuclidines 失效
    取代的3-氨基亚奎宁

    公开(公告)号:US5716965A

    公开(公告)日:1998-02-10

    申请号:US175353

    申请日:1993-12-20

    IPC分类号: C07D453/02 A61K31/445

    CPC分类号: C07D453/02

    摘要: Compounds of the formula ##STR1## wherein W, Ar.sup.1, Ar.sup.2 and Ar.sup.3 are defined as below; and the pharmaceutically acceptable salts of such compounds. These compounds are substance P antagonists and useful in the treatment of gastrointestinal disorders, inflammatory disorders, central nervous system disorders and pain.

    摘要翻译: PCT No.PCT / US92 / 04002 Sec。 371日期:1993年12月20日 102(e)1993年12月20日日期PCT提交1992年5月19日PCT公布。 出版物WO92 / 20676 日期:1992年11月26日其中W,Ar 1,Ar 2和Ar 3如下定义的式(Ⅰ)化合物: 和这些化合物的药学上可接受的盐。 这些化合物是物质P拮抗剂,可用于治疗胃肠道疾病,炎性疾病,中枢神经系统疾病和疼痛。

    Substituted quinuclidines as substance P antagonists
    3.
    发明授权
    Substituted quinuclidines as substance P antagonists 失效
    取代的奎宁化合物作为P物质拮抗剂

    公开(公告)号:US5837711A

    公开(公告)日:1998-11-17

    申请号:US428240

    申请日:1995-04-28

    IPC分类号: C07D453/02 A61K31/44

    CPC分类号: C07D453/02

    摘要: Certain novel substituted quinuclidine compounds having the ability to antagonize substance P and having the following formula: ##STR1## wherein Ar.sup.1 and Ar.sup.2 are each, independently, thienyl, phenyl, fluorophenyl, chlorophenyl or bromophenyl; X is --CONR.sup.3 R.sup.4, --CO.sub.2 R.sup.3, --CH.sub.2 OR.sup.3, --CH.sub.2 NR.sup.3 R.sup.4 or --CONR.sup.3 OR.sup.4 ; R.sup.1, R.sup.3 and R.sup.4 are each, independently, hydrogen or alkyl having 1 to 4 carbon atoms; R.sup.2 is alkyl having 1 to 4 carbon atoms; Y is alkylsulfonyl having 1 to 4 carbon atoms, N-alkyl-N-alkanoylamino (which may be substituted by halogen in the alkanoyl moiety) having 1 to 4 carbon atoms in the alkyl and the alkanoyl moieties, N-alkyl-N-alkylsulfonylamino (which may be substituted by halogen in the alkylsulfonyl moiety) having 1 to 4 carbon atoms in the alkyl and the alkyl sulfonyl moieties, alkenyl having 2 to 4 carbon atoms, alkynyl having 2 to 4 carbon atoms, halosubstituted alkyl having 1 to 4 carbon atoms, alkylamino having 1 to 4 carbon atoms, alkanoylamino (which may be substituted by halogen) having 1 to 4 carbon atoms or alkylsulfonylamino (which may be substituted by halogen) having 1 to 4 carbon atoms. These compounds are useful in the treatment gastrointestinal or central nervous system disorders and the alleviation of inflammatory diseases, asthma, pain and migraine in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.

    摘要翻译: PCT No.PCT / US93 / 09169 Sec。 371日期:1995年4月28日 102(e)日期1995年4月28日PCT 1993年9月30日PCT公布。 出版物WO94 / 10170 日期:1994年5月11日具有拮抗物质P并具有下式的新颖取代的奎宁环化合物:其中Ar 1和Ar 2各自独立地为噻吩基,苯基,氟苯基,氯苯基或溴苯基; X是-CONR 3 R 4,-CO 2 R 3,-CH 2 OR 3,-CH 2 NR 3 R 4或-CONR 3 OR 4; R 1,R 3和R 4各自独立地为氢或具有1至4个碳原子的烷基; R2是具有1至4个碳原子的烷基; Y是具有1至4个碳原子的烷基磺酰基,在烷基和烷酰基部分中具有1至4个碳原子的N-烷基-N-烷酰基氨基(其可被烷酰基部分中被卤素取代)为N-烷基-N-烷基磺酰基氨基 (其可以被烷基磺酰基部分中的卤素取代)在烷基和烷基磺酰基部分中具有1至4个碳原子,具有2至4个碳原子的烯基,具有2至4个碳原子的炔基,具有1至4个碳原子的卤代烷基 原子,具有1至4个碳原子的烷基氨基,具有1至4个碳原子的烷酰基氨基(其可以被卤素取代)或具有1至4个碳原子的烷基磺酰基氨基(可被卤素取代)。 这些化合物可用于治疗哺乳动物的胃肠道或中枢神经系统疾病和减轻炎性疾病,哮喘,疼痛和偏头痛,并用作用于治疗这些病症的药物组合物中的活性成分。

    Substituted benzylaminoquinuclidines as substance P antagonists
    9.
    发明授权
    Substituted benzylaminoquinuclidines as substance P antagonists 失效
    取代的苄基氨基奎宁啶作为物质P拮抗剂

    公开(公告)号:US5604241A

    公开(公告)日:1997-02-18

    申请号:US416913

    申请日:1995-04-20

    CPC分类号: C07F9/6561 C07D453/02

    摘要: Compounds useful in the treatment of inflammatory disorders, central nervous system disorders and other disorders of the formula I ##STR1## and the pharmaceutically-acceptable salts thereof, wherein Ar.sup.1 and Ar.sup.2 are each independently aryl or substituted aryl; R.sup.1 is alkyl having from 1 to 6 carbon atoms;R.sup.2 is hydrogen or alkyl having from 1 to 6 carbon atoms;and either X and Y are taken separately and they are each, independently, hydrogen, dialkylphosphoryl having 2 to carbon atoms, alkyl having from 1 to 6 carbon atoms, alkenyl having from 2 to 6 carbon atoms or alkynyl having from 2 to 6 carbon atoms; or X and Y are taken together and they represent a hydrocarbon chain having 3, 4, or 5 carbon atoms, optionally containing up to 2 double bonds and optionally having 1 or 2 substituents selected from oxo, hydroxy and alkyl having from 1 to 6 carbon atoms; or Y is methoxy when X is ethyl; provided that when X and Y are taken together they are attached to adjacent carbon atoms; and provided that if either X or Y is hydrogen, then the other one must be alkenyl or alkynyl; and provided that when Y is methoxy and X is ethyl, then Y is at the 4-position and X is at the 5-position, Ar.sup.1 or Ar.sup.2 must each be phenyl, R.sup.1 is methyl and R.sup.2 is hydrogen.

    摘要翻译: PCT No.PCT / US93 / 09168 Sec。 371日期1995年04月20日 102(e)1995年4月20日PCT PCT 1993年9月30日PCT公布。 公开号WO94 / 08997 日期1994年4月28日可用于治疗炎症性疾病,中枢神经系统疾病和式I的其它病症及其药学上可接受的盐的化合物,其中Ar1和Ar2各自独立地为芳基或取代的芳基; R1是具有1至6个碳原子的烷基; R2是氢或具有1至6个碳原子的烷基; X和Y分开取代,它们各自独立地为氢,具有2-碳原子的二烷基磷酰基,具有1-6个碳原子的烷基,具有2-6个碳原子的链烯基或具有2-6个碳原子的炔基 ; 或X和Y一起并且它们表示具有3,4或5个碳原子的烃链,任选地含有至多2个双键并且任选地具有1或2个选自氧代,羟基和具有1至6个碳原子的烷基的取代基 原子 或当X为乙基时,Y为甲氧基; 条件是当X和Y一起取代时,它们连接到相邻的碳原子上; 并且条件是如果X或Y是氢,则另一个必须是烯基或炔基; 并且条件是当Y为甲氧基且X为乙基时,则Y为4-位,X为5-位,Ar1或Ar2各自为苯基,R1为甲基,R2为氢。